Industry News
Science and censorship: the deadly H5N1 paper debate
Scientists have reacted with consternation to news that key details will be removed from a paper outlining a new mutant and potentially deadly H5N1 virus. [ + ]
Viralytics raises $4.7m to fund melanoma trial
Cash levels boosted to over $8 million to help fund phase II melanoma trial. [ + ]
Feature: The delicate immunological negotiation of sex
Reproduction doesn’t just involve a negotiation process between partners, but it involves a complex interaction at the immune level. [ + ]
Trial success sees Clinuvel near European filing for Scenesse
Clinuvel’s photoprotective drug Scenesse has shown it has a significant benefit for sufferers of erythropoietic protoporphyria, bringing the company closer to filing in Europe for marketing authorisation. [ + ]
A look at year that was and what’s in store for 2012
In the year that AusBiotech celebrated 25 years since it began as the Australian Biotechnology Association, 2011 has been the most action-packed for many years. Dr Anna Lavelle, CEO of AusBiotech, takes a look at the year that was and what 2012 might hold for the biotechnology sector. [ + ]
HealthLinx prepares to wrap up OvPlex trial
Diagnostics product developer HealthLinx (ASX:HTX) will finalise recruitment for a large trial of its OvPlex ovarian cancer biomarker, on the strength of the early results. [ + ]
Hunter Immunology agrees to Probiomics merger
The board and largest shareholders of Hunter Immunology have agreed to endorse a reverse takeover by Probiomics (ASX:PCC) to create a company with a $37.2m market cap. [ + ]
Prof Ian Frazer elected to Australian Academy of Science council
Professor Ian Frazer, who was named Australian of the Year in 2006 for his development of the human papillomavirus (HPV) cervical cancer vaccines, has become one of the most recent members of the Australian Academy of Science, alongside a Nobel Laureate, a Eureka prize winner and a pioneer in mathematics.
[ + ]Researchers in Sydney Blaze ahead with world-leading microscope technology
The world’s first system for studying the cell biology of living microorganisms at super-resolution has been installed at the University of Technology, Sydney, promising new insights into the behaviour of infectious diseases.
[ + ]BioDiem buys Savine Therapeutics
Vaccine company BioDiem (ASX:BDM) has added antigen development technology to its portfolio with the purchase of Savine Therapeutics. [ + ]
IQnovate completes public listing on NSX
Shares in contract medical services company IQnovate (NSX:IQN) start strong, but then pare some of their early gains, during the first day of public trading. [ + ]
UTS installs live super-resolution microscope
A super-resolution imaging system that can produce real-time footage of living cells has been installed in the University of Technology Sydney. [ + ]
Compumedics wins $1m EEG deal
Compumedics (ASX:CMP) has picked up a deal to supply an EEG system to the Yale School of Medicine. [ + ]
Government must do more to promote ethical standards in the promotion of health sector products: IVD Australia
IVD Australia has expressed disappointment that the Therapeutic Goods Administration's new blueprint on regulation of the promotion of therapeutic goods doesn't do enough to raise ethical standards in the industry. [ + ]
Phylogica partnership with Pfizer hits first milestone
Drug discovery company Phylogica (ASX:PYC) has received its first milestone payment from a collaboration with Pfizer to discover novel peptide-based vaccines. [ + ]
